Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.

AOR Nattokinase (Ultra)

Report a Concern
Starting date:
December 6, 2006
Posting date:
March 5, 2007
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type II
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-2007A14

Recalled Products

A. AOR Nattokinase (Ultra)

Reason

As a result of a trade complaint, the HPFB Inspectorate requested a Health Hazard Evaluation of these products. NHPD's HHE responses classified both products as a Type II Health Hazard due to the label indication that the product supports fibrinolysis, the breaking up of thrombi by reducing excessive levels of plasminogen activator inhibitor type 1, which implies that it may be used to treat embolic or thrombotic disorders and indicates that it may interact with other prescription or non-prescription fibrinolytic or blood-thinning drugs. 

Affected products

AOR Nattokinase (Ultra)

DIN, NPN, DIN-HIM
N/A
Dosage form

Vegi-Cap

Strength

100 mg

Lot or serial number

303SE06A

Companies
Recalling Firm
Advanced Orthomolecular Research Inc.
9 - 4101 19 St NE
Calgary
T2E 6X8
Alberta
CANADA
Marketing Authorization Holder
N/A